BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 16137768)

  • 1. Genetic and fluorescence studies of affinity maturation in related antibodies.
    Pauyo T; Hilinski GJ; Chiu PT; Hansen DE; Choi YJ; Ratner DI; Shah-Mahoney N; Southern CA; O'Hara PB
    Mol Immunol; 2006 Mar; 43(7):812-21. PubMed ID: 16137768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational analysis of the affinity maturation of antibody 48G7.
    Yang PL; Schultz PG
    J Mol Biol; 1999 Dec; 294(5):1191-201. PubMed ID: 10600377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of hapten binding and catalytic determinants in a family of catalytic antibodies.
    Ulrich HD; Schultz PG
    J Mol Biol; 1998 Jan; 275(1):95-111. PubMed ID: 9451442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent somatic mutations in mouse antibodies to p-azophenylarsonate increase affinity for hapten.
    Sharon J; Gefter ML; Wysocki LJ; Margolies MN
    J Immunol; 1989 Jan; 142(2):596-601. PubMed ID: 2911012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategy for affinity maturation of an antibody with high evolvability to (4-hydroxy-3-nitrophenyl) acetyl hapten.
    Furukawa K; Shimizu T; Murakami A; Kono R; Nakagawa M; Sagawa T; Yamato I; Azuma T
    Mol Immunol; 2007 Mar; 44(9):2436-45. PubMed ID: 17118452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-reactive binding of cyclic peptides to an anti-TGFalpha antibody Fab fragment: an X-ray structural and thermodynamic analysis.
    Hahn M; Winkler D; Welfle K; Misselwitz R; Welfle H; Wessner H; Zahn G; Scholz C; Seifert M; Harkins R; Schneider-Mergener J; Höhne W
    J Mol Biol; 2001 Nov; 314(2):293-309. PubMed ID: 11718562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can immunoglobulin C(H)1 constant region domain modulate antigen binding affinity of antibodies?
    Pritsch O; Hudry-Clergeon G; Buckle M; Petillot Y; Bouvet JP; Gagnon J; Dighiero G
    J Clin Invest; 1996 Nov; 98(10):2235-43. PubMed ID: 8941639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies.
    Acierno JP; Braden BC; Klinke S; Goldbaum FA; Cauerhff A
    J Mol Biol; 2007 Nov; 374(1):130-46. PubMed ID: 17916365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.
    Finlay WJ; Cunningham O; Lambert MA; Darmanin-Sheehan A; Liu X; Fennell BJ; Mahon CM; Cummins E; Wade JM; O'Sullivan CM; Tan XY; Piche N; Pittman DD; Paulsen J; Tchistiakova L; Kodangattil S; Gill D; Hufton SE
    J Mol Biol; 2009 May; 388(3):541-58. PubMed ID: 19285987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural elements controlling anti-DNA antibody affinity and their relationship to anti-phosphorylcholine activity.
    Pewzner-Jung Y; Simon T; Eilat D
    J Immunol; 1996 Apr; 156(8):3065-73. PubMed ID: 8609430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative analysis of the immunological evolution of antibody 28B4.
    Yin J; Mundorff EC; Yang PL; Wendt KU; Hanway D; Stevens RC; Schultz PG
    Biochemistry; 2001 Sep; 40(36):10764-73. PubMed ID: 11535051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the energy landscape of antibody-antigen complexes: protein dynamics, flexibility, and molecular recognition.
    Thielges MC; Zimmermann J; Yu W; Oda M; Romesberg FE
    Biochemistry; 2008 Jul; 47(27):7237-47. PubMed ID: 18549243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thermodynamic characterization of affinity maturation: the D1.3 antibody and a higher-affinity mutant.
    VanAntwerp JJ; Wittrup KD
    J Mol Recognit; 1998; 11(1-6):10-3. PubMed ID: 10076798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis of affinity maturation of the TEPC15/Vkappa45.1 anti-2-phenyl-5-oxazolone antibodies.
    Scotti C; Gherardi E
    J Mol Biol; 2006 Jun; 359(5):1161-9. PubMed ID: 16682055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interplay between binding energy and catalysis in the evolution of a catalytic antibody.
    Ulrich HD; Mundorff E; Santarsiero BD; Driggers EM; Stevens RC; Schultz PG
    Nature; 1997 Sep; 389(6648):271-5. PubMed ID: 9305839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and characterization of two anti-sweetener single chain antibodies using radioligand binding, fluorescence and circular dichroism spectroscopy.
    Pledger DW; Brodnicki TC; Graham BL; Tetin S; Kranz DM; Linthicum DS
    J Mol Recognit; 1999; 12(4):258-66. PubMed ID: 10440997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial repertoire of anti-(4-hydroxy-3-nitrophenylacetyl) antibodies as potential donors for effective affinity maturation.
    Furukawa K; Manabe A; Furukawa A; Kuba H; Okajima T; Azuma T
    Mol Immunol; 2006 Apr; 43(11):1751-60. PubMed ID: 16406527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermodynamic analysis of additivity between the heavy and light chains in affinity maturation of an antibody.
    Kang J; Warren AS
    Mol Immunol; 2008 Jan; 45(1):304-5. PubMed ID: 17707510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunological evolution of catalysis.
    Patten PA; Gray NS; Yang PL; Marks CB; Wedemayer GJ; Boniface JJ; Stevens RC; Schultz PG
    Science; 1996 Feb; 271(5252):1086-91. PubMed ID: 8599084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatically mutated B cell pool provides precursors for insulin antibodies.
    Thomas JW; Hulbert C
    J Immunol; 1996 Jul; 157(2):763-71. PubMed ID: 8752927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.